107 related articles for article (PubMed ID: 17680465)
1. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.
Piekarska A; Jozefowicz-Korczynska M; Wojcik K; Berkan E
Int J Audiol; 2007 Jul; 46(7):345-50. PubMed ID: 17680465
[TBL] [Abstract][Full Text] [Related]
2. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
[No Abstract] [Full Text] [Related]
4. Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
Zampino R; Costa G; Barillari M; Adinolfi LE; Marrone A
Infez Med; 2012 Jun; 20(2):117-9. PubMed ID: 22767311
[TBL] [Abstract][Full Text] [Related]
5. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Papastergiou V; Skorda L; Lisgos P; Karatapanis S
Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
[No Abstract] [Full Text] [Related]
6. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Formann E; Stauber R; Denk DM; Jessner W; Zollner G; Munda-Steindl P; Gangl A; Ferenci P
Am J Gastroenterol; 2004 May; 99(5):873-7. PubMed ID: 15128353
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil.
Mendes-Corrêa MC; Bittar RS; Salmito N; Oiticica J
Braz J Infect Dis; 2011; 15(1):87-9. PubMed ID: 21412597
[TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient.
Johnson K; Sargent LA; Galizio C; Ubogu EE
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1110-4. PubMed ID: 19047844
[TBL] [Abstract][Full Text] [Related]
10. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Baker RD; Dee D; Baker SS
J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
[TBL] [Abstract][Full Text] [Related]
11. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
12. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Enjoji M; Dainichi T; Gondo H; Urabe K
Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
[TBL] [Abstract][Full Text] [Related]
13. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P
AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063
[No Abstract] [Full Text] [Related]
14. Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin.
Trebst C; Wedemeyer H; Manns MP; Tillmann H; Windhagen A
Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):91-2. PubMed ID: 17206084
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
17. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
Cua IH; Kwan V; Henriquez M; Kench J; George J
Gut; 2006 Oct; 55(10):1521-2. PubMed ID: 16966706
[No Abstract] [Full Text] [Related]
18. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
[TBL] [Abstract][Full Text] [Related]
19. Bilateral sudden sensorineural hearing loss as an initial presentation of myelodysplastic syndrome.
Lee EJ; Yoon YJ
Am J Otolaryngol; 2012; 33(6):782-3. PubMed ID: 22939315
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
